Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by
stopping blood flow to the tumor.
PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in
treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.